CTNNB

TARRYTOWN, N.Y., May 1, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced that data from its Phase 2 clinical trial of lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, in patients with glioblastoma will be featured during an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025, in Chicago and online. Presentation Details: Title: "Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization" Abstract Number: 2016 Session Type and Title: Rapid Oral Abstract – Central Nervous System Tumors Session Date and Time: Saturday, May 31, 2025, 3:00 pm – 4:30 pm CDT Presenting Author: Fabio M. Iwamoto, MD, Division of Neuro-Oncology, New York-Presbyterian/Columbia University Irving Medical Center More information can be found on the 2025 ASCO Annual Meeting website. About Lucicebtide (formerly known as ST101) Lucicebtide, a first-in-class antagonist of C/EBPβ, has completed the main portion of a Phase 2 dose expansion study in recurrent glioblastoma (rGBM) (NCT04478279). An ongoing window-of-opportunity sub-study is evaluating lucicebtide in combination with radiation and temozolomide in patients with newly diagnosed GBM (ndGBM) and as a monotherapy in patients with rGBM, with patients receiving ST101 before and after surgical resection in both cohorts. ST101 has been granted Fast Track designation for rGBM from the U.S. Food and Drug Administration (U.S. FDA) and orphan designations for glioma from the U.S. FDA and the European Commission. About Sapience Therapeutics Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immune dysregulation that drive cancer. With in-house discovery capabilities, Sapience has built a pipeline of therapeutic candidates called SPEARs™ (Stabilized Peptides Engineered Against Regulation) that disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. Sapience can also direct cargo to cell surface targets with their new class of molecule called SPARCs™ (Stabilized Peptides Against Receptors on Cancer), enabling delivery of radioisotope payloads such as α-particles to cancer cells. Sapience is advancing its lead programs, lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, and ST316, a first-in-class antagonist of β-catenin, through Phase 2 clinical trials. For more information on Sapience Therapeutics, please visit and engage with us on LinkedIn. SOURCE Sapience Therapeutics, Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

New funds provided largely by existing investors, led by Sandwater Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer Research UK and the Norwegian Cancer Society New preclinical data highlighting potential of CY-101 in ACC and other cancer types driven by a dysfunctional Wnt/β-catenin pathway, including colorectal cancer, to be presented at AACR annual meeting April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that it has raised NOK62 million (US$6m) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101 into a multi-national Phase 2 clinical trial in patients with adrenocortical carcinoma due to start in late 2025 and with first clinical readouts expected in 2026. The trial will be conducted through a partnership between Cytovation, Cancer Research UK and the Norwegian Cancer Society under an agreement announced in January 2025 (click here for press release). CY-101, a membranolytic inhibitor of the Wnt/β-catenin pathway, has demonstrated early signs of antitumor activity in the Phase 1 CICILIA trial – particularly in tumors with dysregulated Wnt/β-catenin signaling. New preclinical data being presented at the American Association of Cancer Research (AACR) annual meeting (Chicago, IL; April 25-30, 2025) by Cytovation and its collaborators at the Luxembourg Institute of Health, provide further insights into the mechanistic basis of CY-101’s activity. The studies, conducted in in vivo immune-refractory models of ACC, colorectal carcinoma (CRC) and melanoma, demonstrated that CY-101 eliminates ACC and CRC tumors, enhances the efficacy of anti-PD-1 activity and triggers a systemic antitumor immune response. These findings support the potential of CY-101 as a novel therapeutic for difficult-to-treat cancers such as ACC, and more broadly for tumors with dysregulated Wnt/β-catenin signaling, like CRC and hepatocellular carcinoma (HCC), among others. “As we continue to explore the novel mechanism of action of CY-101 and its translation into meaningful clinical activity, our conviction in its potential to address tumors driven by the Wnt/β-catenin pathway only grows stronger,” said Lars Prestegarden, CEO of Cytovation. “We are grateful for the continued support of our investors, whose confidence – alongside the strength of our outstanding partners – positions us well to advance CY-101 into Phase 2 trials and generate impactful clinical data.” Poster Presentation at AACR Title CY-101 Inhibits Tumor Growth and Improves Anti-PD-1 Immunotherapy in Beta-Catenin-Driven Tumors Poster Number 2231 Session Title PO.IM01.02 - Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression Date / Time April 28, 9:00am-12:00pm Central Time Authors Margaux Poussard et al. Link to abstract Abstract 2231 Cytovation-AACR Link to ePoster Poster 2231 Cytovation-AACR (available from 12pm CT on April 28) Cytovation ASA is a clinical stage immune-oncology company focused on the development of CY-101, a first-in-class bifunctional immunotherapy. CY-101 has a unique dual mechanism of action, specifically eliminating cancer cells by targeting the cell membrane and releasing neo-antigens, and by inhibiting the Wnt/β-catenin oncogenic pathway to restrict tumor growth and reverse immune exclusion associated with β-catenin expression. Dysregulation of this pathway has been associated with several different cancer types including colon, liver, uterine, lung and ovarian cancer, among others. This dual mode of action induces a systemic, tumor-specific immune response. The content above comes from the network. if any infringement, please contact us to modify.

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform TOKYO, April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc. ("Elix"), effective April 1, 2025. This partnership will accelerate research on these challenging molecular targets by combining PRISM BioLab's proprietary peptide mimetic technology for controlling protein-protein interactions with Elix's cutting-edge AI drug discovery platform. In drug discovery, generating a clinical candidate molecule typically takes long time and requires synthesis of hundreds to thousands of compounds, making research and development efficiency a critical challenge. Through this partnership, PRISM BioLab's proprietary small molecule peptide-mimetic PepMetics® technology will be integrated with Elix's AI drug discovery platform "Elix Discovery™." This collaboration will expand the AI search range to include previously unconsidered small molecules, enabling efficient identification of promising compounds for traditionally difficult targets and accelerating the creation of breakthrough drug candidates. By leveraging both companies' AI capabilities and medicinal chemistry expertise, the partnership aims to reduce time and costs and improve success rate of drug discovery, ultimately delivering innovative treatments for unmet medical needs. Comments from Executives Elix co-founder and CEO Shinya Yuki, Ph.D.: In our previous pilot project with PRISM BioLab, we achieved breakthrough results by creating novel compound candidates with an efficiency that would be unimaginable using conventional approaches. This success clearly demonstrated that the combination of our companies' technologies and expertise holds tremendous potential in drug discovery. I am genuinely looking forward to this business partnership, where we can leverage our complementary strengths to pursue outcomes that neither company could achieve alone. PRISM BioLab CEO Dai Takehara: As we challenge ourselves to 'create new areas of drug discovery' with peptide-mimetic small molecules, AI utilization is essential. We expect our efforts to be significantly accelerated through collaboration with Elix, whose mission is to 'rethink drug discovery.' Our pilot project has already demonstrated the synergistic effect of our technologies and team collaboration, and we will continue to pursue the early creation of groundbreaking new drugs together. PRISM BioLab CTO Tatsuya Toma Ph.D.: Improving drug discovery efficiency is an eternal challenge. Delivering better medicines to patients and healthcare professionals as quickly as possible requires innovation. Our PepMetics® technology has characteristics that are highly compatible with AI applications. Elix is not only a professional in AI and machine learning but also expanding their knowledge and understanding of drug discovery while maintaining a flexible corporate culture. They have shown great interest in PepMetics® features, and I believe we can advance comprehensive drug discovery research together, leveraging PepMetics® characteristics to accelerate the process. About Elix Elix is an AI drug discovery company with the mission of "Rethinking drug discovery". Through their flagship software platform, Elix Discovery™, and collaborative consulting engagements, they work with leading pharmaceutical companies and biotech startups to reduce the enormous costs and time associated with drug discovery, while improving the rate of successful outcomes. They achieve these goals via their company's unique blend of AI engineering and medicinal chemistry expertise that allows them to stay at the forefront of development in both fields, and offer the solutions of tomorrow to the problems of today. About PRISM BioLab PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics. PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceutical Co., Ltd. are in clinical development for cancer and liver disease, respectively. SOURCE PRISM BioLab Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED